RecallRadar

FDA Drug recall D-0469-2024

Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13

On 2024-05-01 the FDA classified a Class III recall of Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13 by Second Tokushima Factory Otsuka Pharmaceutical, citing cross Contamination with Other Products.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0469-2024
ClassificationClass III
Statusongoing
Initiated2024-04-09
Published2024-05-01
Last updated2026-09-13 11:52 UTC
CompanySecond Tokushima Factory Otsuka Pharmaceutical
DistributionUS

Product

Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13

Reason

Cross Contamination with Other Products

Identifiers

ndc59148-006-13
ndc59148-006-92
ndc59148-007-13
ndc59148-007-35
ndc59148-007-94
ndc59148-008-13
ndc59148-008-35
ndc59148-008-95
ndc59148-009-13
ndc59148-009-35
ndc59148-009-95
ndc59148-010-13
ndc59148-010-35
ndc59148-011-13
ndc59148-011-35
code_infoLot # APS00423A, Exp 07/31/2025; APS00222A, Exp 11/30/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0469-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.